Effects of statin and lipoprotein metabolism in heart failure

Journal of Cardiology

Volumn 55, Issue 3, 2010, Pages 287-290

  Miura, Shin ichiro ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Heart failure; Lipids; Lipoprotein; Statin

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; HEART FAILURE; HUMAN; LIPOPROTEIN METABOLISM; PLEIOTROPY; PREDICTION; PROGNOSIS; REVIEW;

HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS;

EID: 77952101142     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2010.02.003     Document Type: Review

References (30)

1. Ramasubbu K., Estep J., White D.L., Deswal A., and Mann D.L. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 51 (2008) 415-426
2. Takemoto M., and Laio J.K. Pleiotropic effects of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
3. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
4. Go A.S., Lee W.Y., Yang J., Lo J.C., and Gurwitz J.H. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296 (2006) 2105-2111
5. Foody J.M., Shah R., Galusha D., Masoudi F.A., Havranek E.P., and Krumholz H.M. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 (2006) 1086-1092
6. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
7. Laufs U., and Liao J.K. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 5 (2003) 372-378
8. Laufs U., and Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273 (1998) 24266-24271
9. Sola S., Mir M.Q., Lerakis S., Tandon N., and Khan B.V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
10. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., Wen J., and Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
11. Pliquett R.U., Cornish K.G., Peuler J.D., and Zucker I.H. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 107 (2003) 2493-2498
12. Teshima Y., Yufu K., Akioka H., Iwao T., Anan F., Nakagawa M., Yonemochi H., Takahashi N., Hara M., and Saikawa T. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction. J Cardiol 53 (2009) 58-64
13. Kadota S., Matsuda M., Izuhara M., Baba O., Moriwaki S., Shioji K., Takeuchi Y., and Uegaito T. Long-term effects of early statin therapy for patients with acute myocardial infarction treated with stent implantation. J Cardiol 51 (2008) 171-178
14. Kjekshus J., Apetrei E., Barrios V., Böhm M., Cleland J.G., Cornel J.H., Dunselman P., Fonseca C., Goudev A., Grande P., Gullestad L., Hjalmarson A., Hradec J., Jánosi A., Kamenský G., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
15. GISSI-HF Investigators, Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., Lucci D., Nicolosi G.L., Porcu M., and Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1231-1239
16. Fellström B.C., Jardine A.G., Schmieder R.E., Holdaas H., Bannister K., Beutler J., Chae D.W., Chevaile A., Cobbe S.M., Grönhagen-Riska C., De Lima J.J., Lins R., Mayer G., McMahon A.W., Parving H.H., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009) 1395-1407
17. Kishi T., Yamada A., Okamatsu S., and Sunagawa K. Atorvastatin might improve ventricular electrostability and decelerate the deterioration of renal function in patients with heart failure and diabetes mellitus. J Cardiol 53 (2009) 341-348
18. Horwich T.B., Hamilton M.A., Maclellan W.R., and Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 (2002) 216-224
19. Horwich T.B., Hernandez A.F., Dai D., Yancy C.W., and Fonarow G.C. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J 156 (2008) 1170-1176
20. Christ M., Klima T., Grimm W., Mueller H.H., and Maisch B. Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J 27 (2006) 691-699
21. Sakatani T., Shirayama T., Suzaki Y., Yamamoto T., Mani H., Kawasaki T., Sugihara H., and Matsubara H. The association between cholesterol and mortality in heart failure. Comparison between patients with and without coronary artery disease. Int Heart J 46 (2005) 619-629
22. Lorgelly P.K., Briggs A.H., Wedel H., Dunselman P., Hjalmarson A., Kjekshus J., Waagstein F., Wikstrand J., Jánosi A., van Veldhuisen D.J., Barrios V., Fonseca C., McMurray J.J., and CORONA Study Group. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-I, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 11 (2009) 281-291
23. Iwaoka M., Obata J.E., Abe M., Nakamura T., Kitta Y., Kodama Y., Kawabata K., Takano H., Fujioka D., Saito Y., Kobayashi T., Hasebe H., and Kugiyama K. Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with nonischemic heart failure. J Card Fail 13 (2007) 247-253
24. Ingelsson E., Arnlöv J., Sundström J., Zethelius B., Vessby B., and Lind L. Novel metabolic risk factors for heart failure. J Am Coll Cardiol 46 (2005) 2054-2060
25. Holme I., Fellstrom B., Jardine A., and Holdaas H. Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL). Atherosclerosis 205 (2009) 522-527
26. Van Linthout S., Spillmann F., Riad A., Trimpert C., Lievens J., Meloni M., Escher F., Filenberg E., Demir O., Li J., Shakibaei M., Schimke I., Staudt A., Felix S.B., Schultheiss H.P., et al. Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy. Circulation 117 (2008) 1563-1573
27. Sumi M., Sata M., Miura S., Rye K.A., Toya N., Kanaoka Y., Yanaga K., Ohki T., Saku K., and Nagai R. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 27 (2007) 813-818
28. Imaizumi S., Miura S., Nakamura K., Kiya Y., Uehara Y., Zhang B., Matsuo Y., Urata H., Ideishi M., Rye K.A., Sata M., and Saku K. Antiarrhythmogenic effect of reconstituted high-density lipoprotein against ischemia/reperfusion in rats. J Am Coll Cardiol 51 (2008) 1604-1612
29. Kiya Y., Miura S., Imaizumi S., Uehara Y., Matsuo Y., Abe S., Jimi S., Urata H., Rye K.A., and Saku K. Reconstituted high-density lipoprotein attenuates postinfarction left ventricular remodeling in rats. Atherosclerosis 203 (2009) 137-144
30. Tsutsui H., Tsuchihashi-Makaya M., and Kinugawa S. Clinical characteristics and outcomes of heart failure with preserved ejection fraction: lessons from epidemiological studies. J Cardiol 55 (2010) 13-22